The ESR2-mediated responses, as studied in Granta-519 MCL tumors, involve the alteration of several signaling pathways in the tumor cells as well in the TME that help to clarify the mechanism for the impaired tumor progression seen by estrogens. Here, ESR2 is linked to neoplasm.